Cost Effectiveness of Trametinib as First-Line (1l) Treatment for Braf V600 Positive Advanced or Metastatic Melanoma — A Canadian Societal Perspective
May 1, 2014, 00:00
10.1016/j.jval.2014.03.485
https://www.valueinhealthjournal.com/article/S1098-3015(14)00536-1/fulltext
Title :
Cost Effectiveness of Trametinib as First-Line (1l) Treatment for Braf V600 Positive Advanced or Metastatic Melanoma — A Canadian Societal Perspective
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(14)00536-1&doi=10.1016/j.jval.2014.03.485
First page :
A83
Section Title :
Cancer
Open access? :
No
Section Order :
1534